ID   MIP/5FU
AC   CVCL_HE61
SY   MIP/5-FU; MIP5FU
DR   cancercelllines; CVCL_HE61
DR   GEO; GSM587039
DR   Wikidata; Q54905752
RX   PubMed=15902309;
RX   PubMed=20835245;
RX   PubMed=25960936;
CC   HLA typing: A*24:02,02:01; B*35:08,35:08; C*07:01,04:01 (PubMed=25960936).
CC   Selected for resistance to: ChEBI; CHEBI_46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H689 ! MIP-101
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 10-04-25; Version: 12
//
RX   PubMed=15902309; DOI=10.1172/JCI23002; PMCID=PMC1090471;
RA   Tai I.T., Dai M., Owen D.A., Chen L.-B.;
RT   "Genome-wide expression analysis of therapy-resistant tumors reveals
RT   SPARC as a novel target for cancer therapy.";
RL   J. Clin. Invest. 115:1492-1502(2005).
//
RX   PubMed=20835245; DOI=10.1038/nmeth.1503;
RA   Griffith M., Griffith O.L., Mwenifumbo J., Goya R., Morrissy A.S.,
RA   Morin R.D., Corbett R.D., Tang M.J., Hou Y.-C., Pugh T.J., Robertson G.,
RA   Chittaranjan S., Ally A., Asano J.K., Chan S.Y., Li H.-Y.I.,
RA   McDonald H., Teague K., Zhao Y.-J., Zeng T., Delaney A., Hirst M.,
RA   Morin G.B., Jones S.J.M., Tai I.T., Marra M.A.;
RT   "Alternative expression analysis by RNA sequencing.";
RL   Nat. Methods 7:843-847(2010).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//